Literature DB >> 21681522

Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.

Paul A Northcott1, Thomas Hielscher, Adrian Dubuc, Stephen Mack, David Shih, Marc Remke, Hani Al-Halabi, Steffen Albrecht, Nada Jabado, Charles G Eberhart, Wieslawa Grajkowska, William A Weiss, Steven C Clifford, Eric Bouffet, James T Rutka, Andrey Korshunov, Stefan Pfister, Michael D Taylor.   

Abstract

Recent integrative genomic approaches have defined molecular subgroups of medulloblastoma that are genetically and clinically distinct. Sonic hedgehog (Shh) medulloblastomas account for one-third of all cases and comprise the majority of infant and adult medulloblastomas. To discern molecular heterogeneity among Shh-medulloblastomas, we analyzed transcriptional profiles from four independent Shh-medulloblastoma expression datasets (n = 66). Unsupervised clustering analyses demonstrated a clear distinction between infant and adult Shh-medulloblastomas, which was reliably replicated across datasets. Comparison of transcriptomes from infant and adult Shh-medulloblastomas revealed deregulation of multiple gene families, including genes implicated in cellular development, synaptogenesis, and extracellular matrix maintenance. Furthermore, metastatic dissemination is a marker of poor prognosis in adult, but not in pediatric Shh-medulloblastomas. Children with desmoplastic Shh-medulloblastomas have a better prognosis than those with Shh-medulloblastomas and classic histology. Desmoplasia is not prognostic for adult Shh-medulloblastoma. Cytogenetic analysis of a large, non-overlapping cohort of Shh-medulloblastomas (n = 151) revealed significant over-representation of chromosome 10q deletion (P < 0.001) and MYCN amplification (P < 0.05) in pediatric Shh cases compared with adults. Adult Shh-medulloblastomas harboring chromosome 10q deletion, 2 gain, 17p deletion, 17q gain, and/or GLI2 amplification have a much worse prognosis as compared to pediatric cases exhibiting the same aberrations. Collectively, our data demonstrate that pediatric and adult Shh-medulloblastomas are clinically, transcriptionally, genetically, and prognostically distinct.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681522      PMCID: PMC4538327          DOI: 10.1007/s00401-011-0846-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  21 in total

1.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Authors:  Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

2.  Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.

Authors:  Andrey Korshunov; Marc Remke; Wiebke Werft; Axel Benner; Marina Ryzhova; Hendrik Witt; Dominik Sturm; Andrea Wittmann; Anna Schöttler; Jörg Felsberg; Guido Reifenberger; Stefan Rutkowski; Wolfram Scheurlen; Andreas E Kulozik; Andreas von Deimling; Peter Lichter; Stefan M Pfister
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.

Authors:  Margaret C Thompson; Christine Fuller; Twala L Hogg; James Dalton; David Finkelstein; Ching C Lau; Murali Chintagumpala; Adekunle Adesina; David M Ashley; Stewart J Kellie; Michael D Taylor; Tom Curran; Amar Gajjar; Richard J Gilbertson
Journal:  J Clin Oncol       Date:  2006-03-27       Impact factor: 44.544

4.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.

Authors:  David W Ellison; James Dalton; Mehmet Kocak; Sarah Leigh Nicholson; Charles Fraga; Geoff Neale; Anna M Kenney; Dan J Brat; Arie Perry; William H Yong; Roger E Taylor; Simon Bailey; Steven C Clifford; Richard J Gilbertson
Journal:  Acta Neuropathol       Date:  2011-01-26       Impact factor: 17.088

Review 5.  Molecular diagnostics of CNS embryonal tumors.

Authors:  Stefan M Pfister; Andrey Korshunov; Marcel Kool; Martin Hasselblatt; Charles Eberhart; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2010-09-30       Impact factor: 17.088

6.  Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors:  Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Sci Transl Med       Date:  2010-09-29       Impact factor: 17.956

7.  Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.

Authors:  H Hahn; C Wicking; P G Zaphiropoulous; M R Gailani; S Shanley; A Chidambaram; I Vorechovsky; E Holmberg; A B Unden; S Gillies; K Negus; I Smyth; C Pressman; D J Leffell; B Gerrard; A M Goldstein; M Dean; R Toftgard; G Chenevix-Trench; B Wainwright; A E Bale
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

8.  Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

Authors:  Charles M Rudin; Christine L Hann; John Laterra; Robert L Yauch; Christopher A Callahan; Ling Fu; Thomas Holcomb; Jeremy Stinson; Stephen E Gould; Barbara Coleman; Patricia M LoRusso; Daniel D Von Hoff; Frederic J de Sauvage; Jennifer A Low
Journal:  N Engl J Med       Date:  2009-09-02       Impact factor: 91.245

Review 9.  Management of and prognosis with medulloblastoma: therapy at a crossroads.

Authors:  Roger J Packer; Gilbert Vezina
Journal:  Arch Neurol       Date:  2008-11

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  91 in total

Review 1.  Sonic hedgehog patterning during cerebellar development.

Authors:  Annarita De Luca; Valentina Cerrato; Elisa Fucà; Elena Parmigiani; Annalisa Buffo; Ketty Leto
Journal:  Cell Mol Life Sci       Date:  2015-10-24       Impact factor: 9.261

Review 2.  Genetic and molecular alterations across medulloblastoma subgroups.

Authors:  Patryk Skowron; Vijay Ramaswamy; Michael D Taylor
Journal:  J Mol Med (Berl)       Date:  2015-09-09       Impact factor: 4.599

3.  Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397).

Authors:  Paul L Moots; Anne O'Neill; Harold Londer; Minesh Mehta; Deborah T Blumenthal; Geoffrey R Barger; Margaret L Grunnet; Stuart Grossman; Mark R Gilbert; David Schiff
Journal:  Am J Clin Oncol       Date:  2018-06       Impact factor: 2.339

Review 4.  Targeted treatment for sonic hedgehog-dependent medulloblastoma.

Authors:  Mark W Kieran
Journal:  Neuro Oncol       Date:  2014-06-20       Impact factor: 12.300

Review 5.  Medulloblastoma biology in the post-genomic era.

Authors:  Tenley C Archer; Scott L Pomeroy
Journal:  Future Oncol       Date:  2012-12       Impact factor: 3.404

6.  Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.

Authors:  Tobias Rausch; David T W Jones; Marc Zapatka; Adrian M Stütz; Thomas Zichner; Joachim Weischenfeldt; Natalie Jäger; Marc Remke; David Shih; Paul A Northcott; Elke Pfaff; Jelena Tica; Qi Wang; Luca Massimi; Hendrik Witt; Sebastian Bender; Sabrina Pleier; Huriye Cin; Cynthia Hawkins; Christian Beck; Andreas von Deimling; Volkmar Hans; Benedikt Brors; Roland Eils; Wolfram Scheurlen; Jonathon Blake; Vladimir Benes; Andreas E Kulozik; Olaf Witt; Dianna Martin; Cindy Zhang; Rinnat Porat; Diana M Merino; Jonathan Wasserman; Nada Jabado; Adam Fontebasso; Lars Bullinger; Frank G Rücker; Konstanze Döhner; Hartmut Döhner; Jan Koster; Jan J Molenaar; Rogier Versteeg; Marcel Kool; Uri Tabori; David Malkin; Andrey Korshunov; Michael D Taylor; Peter Lichter; Stefan M Pfister; Jan O Korbel
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

Review 7.  Molecular markers in pediatric neuro-oncology.

Authors:  Koichi Ichimura; Ryo Nishikawa; Masao Matsutani
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 8.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

Review 9.  Misactivation of Hedgehog signaling causes inherited and sporadic cancers.

Authors:  David R Raleigh; Jeremy F Reiter
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

10.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

Authors:  Marcel Kool; David T W Jones; Natalie Jäger; Paul A Northcott; Trevor J Pugh; Volker Hovestadt; Rosario M Piro; L Adriana Esparza; Shirley L Markant; Marc Remke; Till Milde; Franck Bourdeaut; Marina Ryzhova; Dominik Sturm; Elke Pfaff; Sebastian Stark; Sonja Hutter; Huriye Seker-Cin; Pascal Johann; Sebastian Bender; Christin Schmidt; Tobias Rausch; David Shih; Jüri Reimand; Laura Sieber; Andrea Wittmann; Linda Linke; Hendrik Witt; Ursula D Weber; Marc Zapatka; Rainer König; Rameen Beroukhim; Guillaume Bergthold; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Sabine Schmidt; Stephan Wolf; Chris Lawerenz; Cynthia C Bartholomae; Christof von Kalle; Andreas Unterberg; Christel Herold-Mende; Silvia Hofer; Andreas E Kulozik; Andreas von Deimling; Wolfram Scheurlen; Jörg Felsberg; Guido Reifenberger; Martin Hasselblatt; John R Crawford; Gerald A Grant; Nada Jabado; Arie Perry; Cynthia Cowdrey; Sydney Croul; Gelareh Zadeh; Jan O Korbel; Francois Doz; Olivier Delattre; Gary D Bader; Martin G McCabe; V Peter Collins; Mark W Kieran; Yoon-Jae Cho; Scott L Pomeroy; Olaf Witt; Benedikt Brors; Michael D Taylor; Ulrich Schüller; Andrey Korshunov; Roland Eils; Robert J Wechsler-Reya; Peter Lichter; Stefan M Pfister
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.